Netherlands· NL-e5cd344b1992
Evkeeza 150 mg/ml concentraat voor oplossing voor infusie
A evinacumab product containing evinacumab, registered in Netherlands by Ultragenyx Germany GmbH. The same ATC class is registered in 12 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Evinacumab is registered in 12 of 19 countries.
Countries holding a registration under ATC C10AX17 (evinacumab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Evinacumab · ATC C10AX17
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- EVINACUMAB
- Manufacturer
- Ultragenyx Germany GmbH
- Country
- Netherlands (NL)
- ATC code
- C10AX17
- ATC class
- Evinacumab
- Defined daily dose
- 37.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/21/1551
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Evinacumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceEVKEEZA 150 mg/ml, solution à diluer pour perfusionULTRAGENYX GERMANY (ALLEMAGNE)
- BelgiumEvkeeza 150 mg/mlUltragenyx Germany
- CzechiaEVKEEZAUltragenyx Germany GmbH, Berlín
- United StatesEvkeezaRegeneron Pharmaceuticals, Inc.
- SpainEVKEEZA 150 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONUltragenyx Germany Gmbh
- FinlandEvkeezaUltragenyx Germany GmbH
- United KingdomEvkeeza 345mg/2.3ml concentrate for solution for infusion vialsUltragenyx UK Ltd
- IrelandEvkeeza 150 mg/ml concentrate for solution for infusionUltragenyx Germany GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Evkeeza
- Liechtenstein · Evkeeza
- Norway · Evkeeza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/41ea5d40-7370-48e6-85e3-d09217742793 GET /v1/drugs/41ea5d40-7370-48e6-85e3-d09217742793?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentraat voor oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/evkeeza-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Evinacumab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp127110",
"excipients": [
"ARGININEHYDROCHLORIDE, (L-)",
"HISTIDINE, (L-)",
"HISTIDINEMONOHYDROCHLORIDE 1-WATER (L-)",
"POLYSORBAAT 80 (E 433)",
"PROLINE, (L-)",
"WATER VOOR INJECTIE"
],
"substances": [
"EVINACUMAB"
],
"leaflet_url": null,
"authorised_at": "2021/06/17",
"procedure_number": "EMEA/H/C/005449",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/21/1551",
"additional_monitoring": "Y"
}See everything about evinacumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.